State Street
PCVX icon

State Street’s Vaxcyte PCVX Stock Holding History

State Street’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258M Sell
4,440,519
-539,486
-11% -$29.3M 0.01% 826
2025
Q4 		$230M Buy
4,980,005
+194,116
+4% +$8.68M 0.01% 868
2025
Q3 		$172M Sell
4,785,889
-156,346
-3% -$5.18M 0.01% 1026
2025
Q2 		$161M Buy
4,942,235
+534,552
+12% +$17.5M 0.01% 1042
2025
Q1 		$166M Sell
4,407,683
-131,723
-3% -$10.5M 0.01% 997
2024
Q4 		$372M Buy
4,539,406
+1,133,663
+33% +$113M 0.01% 627
2024
Q3 		$389M Buy
3,405,743
+38,596
+1% +$3.48M 0.02% 600
2024
Q2 		$254M Buy
3,367,147
+30,055
+0.9% +$2.05M 0.01% 738
2024
Q1 		$228M Sell
3,337,092
-52,436
-2% -$3.63M 0.01% 810
2023
Q4 		$213M Buy
3,389,528
+244,269
+8% +$12.7M 0.01% 807
2023
Q3 		$160M Sell
3,145,259
-18,053
-0.6% -$891K 0.01% 886
2023
Q2 		$158M Buy
3,163,312
+87,296
+3% +$4.14M 0.01% 929
2023
Q1 		$115M Sell
3,076,016
-91,965
-3% -$3.9M 0.01% 1087
2022
Q4 		$152M Buy
3,167,981
+1,174,945
+59% +$46.1M 0.01% 907
2022
Q3 		$47.8M Buy
1,993,036
+137,392
+7% +$3.48M ﹤0.01% 1620
2022
Q2 		$40.4M Buy
1,855,644
+471,476
+34% +$10.9M ﹤0.01% 1791
2022
Q1 		$33.4M Buy
1,384,168
+209,237
+18% +$4.57M ﹤0.01% 2025
2021
Q4 		$28M Buy
1,174,931
+38,677
+3% +$900K ﹤0.01% 2221
2021
Q3 		$28.8M Sell
1,136,254
-367,009
-24% -$8.9M ﹤0.01% 2211
2021
Q2 		$33.8M Sell
1,503,263
-268,813
-15% -$5.5M ﹤0.01% 2131
2021
Q1 		$35M Buy
1,772,076
+850,246
+92% +$21.4M ﹤0.01% 1999
2020
Q4 		$24.5M Buy
921,830
+647,789
+236% +$24.1M ﹤0.01% 2119
2020
Q3 		$13.5M Buy
+274,041
New +$10.9M ﹤0.01% 2263

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street's PCVX Position: Q1 2026 in Review

State Street reduced its Vaxcyte (PCVX) stake by 11% in Q1 2026, selling an estimated $29.3M and leaving 4,440,519 shares worth $258M. The position accounts for 0.01% of the portfolio, ranked #826.

State Street first reported a position in PCVX in Q3 2020 and has held it in 23 quarters since. The position peaked at $389M in Q3 2024. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • State Street held 4,440,519 shares of Vaxcyte worth $258M as of Q1 2026.
  • State Street sold 539,486 Vaxcyte shares in Q1 2026, an estimated $29.3M.
  • Vaxcyte made up 0.01% of State Street's portfolio in Q1 2026, its #826 holding.
  • State Street first reported a position in Vaxcyte in Q3 2020 and has held it in 23 quarters since.
  • State Street's Vaxcyte position peaked at $389M in Q3 2024.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.